Is There Still a Role for Ultrafiltration in the Management of Acute Heart Failure? CARRESS and Beyond
- First Online:
- Cite this article as:
- Ryan, J. & Meng, S. Curr Heart Fail Rep (2013) 10: 185. doi:10.1007/s11897-013-0142-z
The Cardiorenal Rescue Study in Acute Decompensated Heart Failure (CARRESS-HF) trial was a prospective, randomized study comparing ultrafiltration versus pharmacological therapy in the treatment of acute decompensated heart failure (ADHF) complicated by cardiorenal syndrome Bart et al. (N Eng J Med 367:2296–2304, 1). The study found that ultrafiltration was inferior to pharmacological therapy, resulting in a significant increase in serum creatinine and serious adverse events while producing no significant difference in weight loss. The CARRESS trial calls into question the viability of ultrafiltration as a preferable treatment strategy in ADHF patients with cardiorenal syndrome.